Focus: Stoke Therapeutics is a public biotech company focused on antisense oligonucleotide (ASO) medicines for gene therapy applications, headquartered in Bedford, MA. The company is early-stage with minimal commercial revenue and a pipeline concentrated in rare neurological and genetic disorders.
Profile data last refreshed 16h ago · AI intelligence enriched 3w ago
Growing — net +11 jobs in 30d
18 jobs added vs 7 removed. Steady team buildout.
Stoke offers exposure to cutting-edge ASO science and rare disease focus, but significant cash burn and lack of commercial traction create meaningful career stability risk for all-but-equity-motivated candidates.
Help build intelligence for Stoke Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Stoke Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Siren L.L.C. Sells 252,000 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Siren L.L.C. Sells 252,000 Shares of Stoke Therapeutics, Inc. $STOK MarketBeat
Stoke Therapeutics Inc (STOK) - MSN
Stoke Therapeutics Inc (STOK) MSN
Stoke Therapeutics: Its Dravet Syndrome Lead Asset Enters The Last Stretch (NASDAQ:STOK) - Seeking Alpha
Stoke Therapeutics: Its Dravet Syndrome Lead Asset Enters The Last Stretch (NASDAQ:STOK) Seeking Alpha
Stoke Therapeutics (STOK) awards 225,000 stock options to Chief Scientific Officer - Stock Titan
Stoke Therapeutics (STOK) awards 225,000 stock options to Chief Scientific Officer Stock Titan
Stoke Therapeutics (STOK) CSO Thomas McCauley files initial insider report - Stock Titan
Stoke Therapeutics (STOK) CSO Thomas McCauley files initial insider report Stock Titan
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - July 16, 2026 - BioSpace
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - July 16, 2026 BioSpace
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo